Rapid and effective evaluation of cancer treatments

Biovica

Biovica is a biotechnology company whose patented technology platform, DiviTum, measures the cell growth rate of patients with solid cancer tumours. The test is designed to provide a measure of how fast cancer grows, as well as whether targeted cancer treatment is effective. Biovica has initially chosen to focus on evaluating the treatment effect on metastatic breast cancer. The company is in an early commercial phase and currently has sales to the research market. Commercial launch in 2020 is estimated for Europe and the United States.

Financials

BIOVICA

SEKm 2017 2018 2019
Sales 3 3 14
Sales growth (%) 330,9 -8,2 470
EBITDA -15 -16 -14
EBITDA margin (%) -558,9 -644 -94,9
EBIT adj -18 -19 -18
EBIT adj margin (%) -659,4 -776 -126,5
Pretax profit -18 -19 -18
EPS rep -1,02 -1,1 -1,03
EPS growth (%) -21,3 -7,7 7,1
EPS adj -1,02 -1,1 -1,03
DPS 0 0 0
EV/EBITDA (x) -9 -8,1 -13,3
EV/EBIT adj (x) -7,7 -6,7 -10
P/E (x) -11,3 -8,9 -9,5
P/E adj (x) -11,3 -8,9 -9,5
EV/sales (x) 50,5 51,9 12,6
FCF yield (%) -10,9 -13,9 -14,3
Dividend yield (%) 0 0 0
Net IB debt/EBITDA 4,3 2,6 -0,6

Main shareholders

Biovica

Main shareholders Share capital % Voting shares %
Anders Rylander 22.3 % 33.4 %
Gunnar Rylander 5.6 % 8.6 %
Kristina Gronowitz 2.3 % 3.7 %
Mats Danielsson 1.7 % 2.2 %
Avanza Pension 4.0 % 2.1 %
LYM Consulting AB 2.8 % 1.5 %
Ålandsbanken Fonder 2.4 % 1.3 %
Nordnet Pensionsförsäkring 2.3 % 1.2 %
Per Stålhandske 1.7 % 0.9 %
Lars Holmqvist 1.6 % 0.8 %